Paper Details

  1. Home
  2. Paper Details

Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate asthma.

Author: , BousheyHomer A, ChinchilliVernon M, CraigTimothy J, DeykinAaron, DiMangoEmily, FahyJohn V, IsraelElliot, KraftMonica, KunselmanSusan J, LazarusStephen C, LemanskeRobert F, LeoneFrank, MartinRichard J, PesolaGene R, PetersStephen P, SorknessChristine A, SzeflerStanley J, WechslerMichael E

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The study discussed the complementary effects of long-acting beta-agonists (LABAs) and inhaled corticosteroids on asthma control, as well as the potential complementarity of LABAs and leukotriene receptor antagonists (LTRAs).
Paper Details　
Original Abstract of the Article :
Long-acting beta-agonists (LABAs) and inhaled corticosteroids administered together appear to be complementary in terms of effects on asthma control. The elements of asthma control achieved by LABAs (improved lung function) and leukotriene receptor antagonists (LTRAs; protection against exacerbation...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1899264/

データ提供：米国国立医学図書館（NLM）

Synergy in Asthma Treatment: Combining LABAs and LTRAs

Asthma, a chronic lung condition, presents a significant challenge in healthcare. This study, published in 2006, explores the potential benefits of combining long-acting beta-agonists (LABAs) and leukotriene receptor antagonists (LTRAs) for managing moderate asthma. The authors suggest that these two types of medications may work synergistically, providing a comprehensive approach to asthma control.

A Team Effort in Asthma Management

The study highlights the complementary effects of LABAs and LTRAs in asthma control. LABAs, like a calming breeze, help improve lung function, while LTRAs, acting like a shield, protect against asthma exacerbations. This combined approach could potentially lead to improved asthma control and reduced symptom severity.

Navigating the Asthma Desert

Imagine the airways of an asthma patient as a vast desert landscape, prone to sudden dust storms (exacerbations). LABAs and LTRAs, like a combination of windbreakers and sand-resistant goggles, provide protection and relief, helping individuals navigate the challenges of asthma. This study underscores the importance of personalized treatment strategies tailored to individual needs and circumstances.

Dr.Camel's Conclusion

This research underscores the potential for synergistic approaches in asthma management. Combining LABAs and LTRAs may offer a more comprehensive and effective treatment strategy, leading to improved asthma control and quality of life for individuals with moderate asthma. As a wise traveler in a desert learns to utilize all available resources for survival, individuals with asthma should explore all treatment options to manage their condition effectively.

Date :
  1. Date Completed 2007-03-09
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

16973987

DOI: Digital Object Identifier

PMC1899264

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.